|Awarded On||August 16, 2023|
|Title||A Role for PSMD2, PSMD7, and PSMD9 in Drug Resistance of Acute Myeloid Leukemia (AML)|
|Award Mechanism||TREC: Pilot Study Award|
|Institution/Organization||Texas Tech University Health Sciences Center at El Paso|
|Principal Investigator/Program Director||Anna Eiring|
Acute myeloid leukemia (AML) is a highly aggressive form of cancer arising from the presence of abnormal white blood cells in the bone marrow. While many AML patients initially respond well to therapy, the 5-year survival rate is poor (less than 25%), due to drug resistance and disease recurrence. Bortezomib, an inhibitor that blocks protein degradation, has shown promising results in the treatment of some AML patients. However, resistance is a clinical problem, and treatment is often associated with significant side effects and eventually drug resistance. The proteasome is an intracellular structure responsible for protein degradation. Standard proteasome inhibitors like bortezomib target ...